// App-Quantinova.ai

: Survival Analysis from the CALGB Study of Lenalidomide Maintenance Therapy in Newly Diagnosed Multiple Myeloma Post-Autologous Stem Cell Transplantation Adjusted for Crossover (Alliance 100104)

Researchers

Presenter

  • Philip L. McCarthy

Principal Investigators

  • Paul Richardson

  • Vera Suman

  • Miranda Cooper

  • Owain Saunders

  • Sujith Dhanasiri

  • Sergio Giralt

  • Kenneth Anderson

  • Edward Stadtmauer

  • Sarah A. Holstein

Medical Centers

  • Department of Medicine, Blood and Marrow Transplant Program, Roswell Park Comprehensive Cancer Center, Buffalo, NY

  • Department of Hematology and Oncology, Dana-Farber/CancerCare, Harvard Medical School, Boston, MA

  • Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN

  • BresMed Health Solutions, Sheffield, United Kingdom

  • Celgene International Sarl, Boudry, Switzerland

  • Pediatric Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY

  • Division of Hematology-Oncology/Department of Medicine, Perelman Center for Advanced Medicine, Philadelphia, PA

  • UNMC Oncology and Hematology Division, Nebraska Medical Center, Omaha, NE

Locations

  • United States

  • United Kingdom

  • Switzerland

Companies

  • BresMed Health Solut

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • Lenalidomide

Outcome

  • N/A

Study Design

  • Cross Over

Phase

  • III

Study Id's

  • NCT00114101

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved